Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia | Zendy

Ehab Atallah | Zendy; Charles A. Schiffer | Zendy; Jerald P. Radich | Zendy; Kevin P. Weinfurt | Zendy; Mei-Jie Zhang | Zendy; Javier PinillaIbarz | Zendy; Vamsi Kota | Zendy; Richard A. Larson | Zendy; Joseph O. Moore | Zendy; Michael J. Mauro | Zendy; Michael W. Deininger | Zendy; James E. Thompson | Zendy; Vivian G. Oehler | Zendy; Martha Wadleigh | Zendy; Neil P. Shah | Zendy; Ellen K. Ritchie | Zendy; Richard T. Silver | Zendy; Jorge E. Cortés | Zendy; Li Lin | Zendy; Alexis Visotcky | Zendy; Arielle Baim | Zendy; Jill Harrell | Zendy; Bret Helton | Zendy; Mary M. Horowitz | Zendy; Kathryn E. Flynn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia

Author(s) -

Ehab Atallah,

Charles A. Schiffer,

Jerald P. Radich,

Kevin P. Weinfurt,

Mei-Jie Zhang,

Javier PinillaIbarz,

Vamsi Kota,

Richard A. Larson,

Joseph O. Moore,

Michael J. Mauro,

Michael W. Deininger,

James E. Thompson,

Vivian G. Oehler,

Martha Wadleigh,

Neil P. Shah,

Ellen K. Ritchie,

Richard T. Silver,

Jorge E. Cortés,

Li Lin,

Alexis Visotcky,

Arielle Baim,

Jill Harrell,

Bret Helton,

Mary M. Horowitz,

Kathryn E. Flynn

Publication year - 2020

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2020.5774

Subject(s) - medicine , discontinuation , dasatinib , nilotinib , bosutinib , imatinib , adverse effect , myeloid leukemia , hazard ratio , oncology , confidence interval

Tyrosine kinase inhibitors (TKIs) have been associated with improved survival of patients with chronic myeloid leukemia (CML) but are also associated with adverse effects, especially fatigue and diarrhea. Discontinuation of TKIs is safe and is associated with the successful achievement of treatment-free remission (TFR) for some patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research